Janssen files novel TB drug in the EU
This article was originally published in Scrip
Executive Summary
Janssen-Cilag International has filed for EU approval for bedaquiline (TMC207) as an oral treatment for use as part of a combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults.